Morepen Laboratories Limited (MOREPENLAB.BO)
INR 83.77
(-0.35%)
INR 83.77
(-0.35%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.72 Billion INR | 85.17% |
| 2022 | 856.66 Million INR | -45.36% |
| 2021 | 1.56 Billion INR | 20.51% |
| 2020 | 1.28 Billion INR | 67.84% |
| 2019 | 779.98 Million INR | 9.64% |
| 2018 | 711.89 Million INR | 4.02% |
| 2017 | 684.5 Million INR | 5.19% |
| 2016 | 650.95 Million INR | 2.94% |
| 2015 | 625.79 Million INR | 26.53% |
| 2014 | 496.04 Million INR | -1.03% |
| 2013 | 530.2 Million INR | 48.2% |
| 2012 | 369.1 Million INR | 65.78% |
| 2011 | 324.5 Million INR | 199.56% |
| 2010 | 68.1 Million INR | -40.72% |
| 2009 | 453.45 Million INR | 138.99% |
| 2008 | 125.44 Million INR | 597.68% |
| 2007 | 119.35 Million INR | -105.53% |
| 2006 | -672.92 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 516.18 Million INR | 4.6% |
| 2023 Q1 | 285.08 Million INR | 52.6% |
| 2023 FY | - INR | 85.17% |
| 2023 Q4 | 483.8 Million INR | -11.45% |
| 2023 Q3 | 546.37 Million INR | 48.36% |
| 2023 Q2 | 368.26 Million INR | 29.18% |
| 2022 Q3 | 217.42 Million INR | -27.0% |
| 2022 Q1 | 154.58 Million INR | -60.13% |
| 2022 Q2 | 297.83 Million INR | 92.67% |
| 2022 FY | - INR | -45.36% |
| 2022 Q4 | 186.81 Million INR | -14.08% |
| 2021 FY | - INR | 20.51% |
| 2021 Q3 | 348.13 Million INR | -17.16% |
| 2021 Q4 | 387.74 Million INR | 11.38% |
| 2021 Q1 | 454.31 Million INR | 127.08% |
| 2021 Q2 | 420.26 Million INR | -7.5% |
| 2020 Q2 | 354.88 Million INR | 27.2% |
| 2020 FY | - INR | 67.84% |
| 2020 Q1 | 279 Million INR | 38.66% |
| 2020 Q4 | 200.06 Million INR | -38.69% |
| 2020 Q3 | 326.3 Million INR | -8.05% |
| 2019 FY | - INR | 9.64% |
| 2019 Q1 | 196.11 Million INR | -11.98% |
| 2019 Q2 | 178.7 Million INR | -8.88% |
| 2019 Q3 | 199.06 Million INR | 11.39% |
| 2019 Q4 | 201.21 Million INR | 1.08% |
| 2018 Q3 | 192.65 Million INR | 14.03% |
| 2018 FY | - INR | 4.02% |
| 2018 Q2 | 168.95 Million INR | 37.89% |
| 2018 Q4 | 222.79 Million INR | 15.64% |
| 2018 Q1 | 122.52 Million INR | -30.64% |
| 2017 Q3 | 190.55 Million INR | -5.31% |
| 2017 Q4 | 176.66 Million INR | -7.29% |
| 2017 FY | - INR | 5.19% |
| 2017 Q1 | 111 Million INR | 0.0% |
| 2017 Q2 | 201.24 Million INR | 81.29% |
| 2016 FY | - INR | 2.94% |
| 2015 FY | - INR | 26.53% |
| 2014 FY | - INR | -1.03% |
| 2013 FY | - INR | 48.2% |
| 2012 Q1 | - INR | 0.0% |
| 2012 FY | - INR | 65.78% |
| 2012 Q2 | - INR | 0.0% |
| 2012 Q3 | - INR | 0.0% |
| 2011 FY | - INR | 199.56% |
| 2010 FY | - INR | -40.72% |
| 2009 FY | - INR | 138.99% |
| 2008 FY | - INR | 597.68% |
| 2007 FY | - INR | -105.53% |
| 2006 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Ajanta Pharma Limited | 12.56 Billion INR | 86.264% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -152.873% |
| Sigachi Industries Limited | 883.39 Million INR | -95.377% |
| Bal Pharma Limited | 345.59 Million INR | -399.42% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 74.846% |
| Medico Remedies Limited | 150.37 Million INR | -1047.744% |
| Lasa Supergenerics Limited | -65.08 Million INR | 2752.05% |
| Venus Remedies Limited | 711.8 Million INR | -142.477% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 146.257% |
| Alpa Laboratories Limited | 86.12 Million INR | -1903.964% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -10.37% |
| Shilpa Medicare Limited | 2.58 Billion INR | 33.309% |
| Aarti Drugs Limited | 3.24 Billion INR | 46.871% |
| Lupin Limited | 36.96 Billion INR | 95.331% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 97.207% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 96.93% |
| Windlas Biotech Limited | 781.72 Million INR | -120.789% |
| Suven Life Sciences Limited | -992.78 Million INR | 273.851% |
| Eris Lifesciences Limited | 6.98 Billion INR | 75.296% |
| Valiant Laboratories Limited | 12.73 Million INR | -13448.583% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 81.511% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 161.163% |
| Ipca Laboratories Limited | 13.29 Billion INR | 87.022% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -16.695% |
| Achyut Healthcare Limited | 524 Thousand INR | -329280.534% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 98.753% |
| Bajaj HealthCare Limited | 444.51 Million INR | -288.277% |
| RPG Life Sciences Limited | 1.28 Billion INR | -34.682% |
| Mankind Pharma Limited | 28.09 Billion INR | 93.857% |
| Laurus Labs Limited | 8 Billion INR | 78.442% |
| Piramal Pharma Limited | 13.05 Billion INR | 86.78% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -301.127% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 95.07% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 82.053% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 84.785% |
| Unichem Laboratories Limited | 742.35 Million INR | -132.497% |
| Sequent Scientific Limited | 549.8 Million INR | -213.924% |
| Novartis India Limited | 1.26 Billion INR | -35.977% |
| Wanbury Limited | 985.49 Million INR | -75.137% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 63.098% |
| Wockhardt Limited | 1.08 Billion INR | -59.811% |
| Themis Medicare Limited | 562.6 Million INR | -206.778% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -433.591% |
| Jubilant Pharmova Limited | 8 Billion INR | 78.442% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 74.851% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 98.045% |
| Divi's Laboratories Limited | 25.43 Billion INR | 93.213% |
| NATCO Pharma Limited | 18.79 Billion INR | 90.817% |
| Gufic Biosciences Limited | 1.48 Billion INR | -16.58% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 33.785% |
| Ind-Swift Limited | 1.06 Billion INR | -62.051% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 42.743% |
| FDC Limited | 4.4 Billion INR | 60.789% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 2186.325% |
| Granules India Limited | 8.6 Billion INR | 79.94% |
| Medicamen Biotech Limited | 245.66 Million INR | -602.578% |
| Alkem Laboratories Limited | 24.19 Billion INR | 92.867% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 26.767% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -13113.551% |
| Brooks Laboratories Limited | 41.72 Million INR | -4036.201% |
| Megasoft Limited | 284.73 Million INR | -506.17% |
| ZIM Laboratories Limited | 462.09 Million INR | -273.505% |
| Strides Pharma Science Limited | 3.76 Billion INR | 54.154% |
| Neuland Laboratories Limited | 4.74 Billion INR | 63.65% |
| Hikal Limited | 2.69 Billion INR | 35.891% |
| Indoco Remedies Limited | 2.64 Billion INR | 34.797% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 55.851% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -500.488% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -886.564% |
| Hester Biosciences Limited | 539.47 Million INR | -219.935% |